Myriad, Epic partner for genetic testing integration
June 24, 2022 -- Myriad Genetics is partnering with Epic to integrate Myriad’s genetic testing line with Epic’s network of physicians and patients. Read More
Illumina launches research test for HRD
June 22, 2022 -- Illumina on Wednesday announced the launch of a next-generation sequencing (NGS)-based research-use-only test for homologous recombination deficiency that it has developed with Merck. Read More
AstraZeneca, G42 Healthcare aim to collaborate
June 21, 2022 -- Abu Dhabi-based G42 Healthcare has signed a letter of intent with AstraZeneca with the aim of expanding their collaboration into diagnostics and clinical research and providing access to treatments for patients in the United Arab Emirates (UAE) and beyond. Read More
Exact Sciences, Ultima Genomics ink supply agreement
June 21, 2022 -- Exact Sciences and Ultima Genomics on Tuesday announced a long-term supply agreement by which Exact will obtain access to Ultima's next-generation sequencing (NGS) technologies. Read More
Veracyte announces evidence supporting thyroid genomic test
June 20, 2022 -- Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules. Read More
Rady Children’s Institute launches newborn genetic disease screening
June 15, 2022 -- Rady Children's Institute for Genomic Medicine (RCIGM) has launched a program that aims to advance newborn screening for treatable genetic diseases through rapid whole-genome sequencing. Read More
Thermo Fisher Scientific obtains CE Mark for NGS, Dx workflows
June 15, 2022 -- Thermo Fisher Scientific has received a CE-IVD Mark under the In Vitro Diagnostic Medical Devices Directive (IVDD) for its Ion Torrent Reporter Software Aneuploidy Dx Workflows for the detection of aneuploidies. Read More
Tempus, Eli Lilly collaborate to expand genomic testing
June 9, 2022 -- Tempus said it will collaborate with Eli Lilly to provide broader access to genomic testing to patients with metastatic non-small cell lung cancer (NSCLC). Read More
ASCO presentation highlights clinical utility of ctDNA testing
June 6, 2022 -- Circulating tumor DNA (ctDNA) has the potential to identify patients with stage II colon cancer who would benefit most from chemotherapy after surgery and separate them from those who could avoid the toxicities of chemotherapy, according to an international study. Read More
Tempus launching liquid biopsy panel
June 6, 2022 -- Tempus is set to launch a new liquid biopsy panel, xF+, that consists of 523 genes and focuses on pathogenic mutations in cell-free DNA. Read More